Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | PGK1 | P00558 | 1/20 | 0.38 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 3/20 | 0.37 |
| ▸ | ESR1 | P03372 | 2/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | FASN | P49327 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29421170 | 1.00 | TSHR (0.52) | TSHRHSD17B10HPGDTRPV4CYP3A4 | |
| SCHEMBL31222234 | 0.91 | TSHR (0.52) | TSHRHSD17B10HPGDTRPV4CYP3A4 | |
| SCHEMBL145418 | 0.84 | TRPV4 (0.54) | TRPV4ALDH1A1PGK1VCAM1AR | |
| SCHEMBL22833461 | 0.80 | TRPV4 (0.45) | TSHRHSD17B10HPGDTRPV4ALDH1A1 | |
| SCHEMBL2131816 | 0.80 | GPR35 (0.44) | TSHRHSD17B10HPGDTRPV4CYP3A4 | |
| SCHEMBL19834113 | 0.80 | HPGD (0.43) | TSHRHSD17B10HPGDTRPV4CYP3A4 | |
| SCHEMBL18586842 | 0.80 | TRPV4 (0.39) | TSHRHSD17B10HPGDTRPV4CYP3A4 | |
| SCHEMBL2262103 | 0.80 | TRPV4 (0.39) | TSHRHSD17B10HPGDTRPV4CYP3A4 | |
| SCHEMBL6502273 | 0.79 | TRPV4 (0.50) | TSHRHSD17B10HPGDTRPV4ALDH1A1 | |
| SCHEMBL10945357 | 0.76 | TRPV4 (0.52) | TRPV4ALDH1A1PGK1VCAM1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0004660-B1 | PROCESS FOR PREPARING 2,5-DICHLORO-4-CYANOPHENOL | CELAMERCK GmbH & Co. KG (DE) | 1981-04-29 | — | — | EP | claimed |
| EP-0004660-A1 | Process for preparing 2,5-dichloro-4-cyanophenol | CELAMERCK GmbH & Co. KG (DE) | 1979-10-17 | — | — | EP | claimed |
| US-20260092064-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | OPPILAN PHARMA LTD. (GB) | 2026-04-02 | — | — | US | disclosed |
| US-20230339944-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | Oppilan Pharma Limited (GB) | 2023-10-26 | — | — | US | disclosed |
| US-20230339944-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | Oppilan Pharma Limited (GB) | 2023-10-26 | — | — | US | disclosed |
| US-20230339944-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | Oppilan Pharma Limited (GB) | 2023-10-26 | — | — | US | disclosed |
| EP-4163281-A1 | PROCESS FOR PREPARING HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE AND INTERMEDIATE COMPOUNDS USED THEREIN | Oppilan Pharma Ltd. (GB) | 2023-04-12 | — | — | EP | disclosed |
| EP-3373931-B1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | OPPILAN PHARMA LTD (GB) | 2022-09-28 | — | — | EP | disclosed |
| US-20220227767-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | OPPILAN PHARMA LTD (GB) | 2022-07-21 | — | — | US | disclosed |
| CN-114149424-A | Heterocyclic compounds for the treatment of diseases | 奥比兰制药有限公司 | 2022-03-08 | — | — | CN | disclosed |
| CN-108463222-B | Heterocyclic compounds for the treatment of diseases | 奥比兰制药有限公司 | 2021-10-22 | — | — | CN | disclosed |
| US-20100160369-A1 | S1P1 Agonists and Methods of Making And Using | EXELIXIS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| WO-2010065760-A1 | IMIDAZO [1,2A] PYRIDINE DERIVATIVES, THEIR USE AS S1P1 AGONISTS AND METHODS FOR THEIR PRODUCTION | EXELIXIS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010065760-A1 | IMIDAZO [1,2A] PYRIDINE DERIVATIVES, THEIR USE AS S1P1 AGONISTS AND METHODS FOR THEIR PRODUCTION | EXELIXIS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| EP-0004660-B1 | PROCESS FOR PREPARING 2,5-DICHLORO-4-CYANOPHENOL | CELAMERCK GmbH & Co. KG (DE) | 1981-04-29 | — | — | EP | disclosed |
| EP-0004660-B1 | PROCESS FOR PREPARING 2,5-DICHLORO-4-CYANOPHENOL | CELAMERCK GmbH & Co. KG (DE) | 1981-04-29 | — | — | EP | disclosed |
| EP-0004660-A1 | Process for preparing 2,5-dichloro-4-cyanophenol | CELAMERCK GmbH & Co. KG (DE) | 1979-10-17 | — | — | EP | disclosed |
| EP-0004660-A1 | Process for preparing 2,5-dichloro-4-cyanophenol | CELAMERCK GmbH & Co. KG (DE) | 1979-10-17 | — | — | EP | disclosed |
| EP-0004660-A1 | Process for preparing 2,5-dichloro-4-cyanophenol | CELAMERCK GmbH & Co. KG (DE) | 1979-10-17 | — | — | EP | disclosed |
| US-4150124-A | INSECTICIDES, MITICIDES, FUNGICIDES | CELAMERCK GMBH & CO. KG (DE) | 1979-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092064-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | XDH, MALT1, CBR1 | TSHR 226/4885HSD17B10 464/4885HPGD 2000/4885 |
| US-20220227767-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | VHL, FH, TPMT | TSHR 2328/4885HSD17B10 395/4885HPGD 118/4885 |
| US-20230339944-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | VHL, FH, TPMT | TSHR 2328/4885HSD17B10 395/4885HPGD 118/4885 |
| US-20100160369-A1 | S1P1 Agonists and Methods of Making And Using | S1PR1, S1PR5, S1PR3 | TSHR 730/4885HSD17B10 1648/4885HPGD 1638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.